AbbVie, University of Chicago’s collaboration for advance cancer research
Posted on23 Apr 2016
Comments0
The University of Chicago and AbbVie, a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve the pace... Read More
Eiger BioPharmaceuticals to Develop BMS’ Lambda for HDV
Posted on23 Apr 2016
TagsBristol-Myers Squibb, Eiger BioPharmaceuticals, HDV infection, hepatitis delta virus, Lonafarnib, Merck
Comments0
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, announced that it has licensed Pegylated Interferon Lambda-1a (Lambda), a novel, well-characterized, first in class... Read More
Sri Krishna Pharma received USFDA warning for cGMP norm violations
The Hyderabad-based Sri Krishna Pharmaceuticals has been warned by US health regulator for violations of good manufacturing practices at its facility, including... Read More
Glenmark receives 3 observations from USFDA for Indore plant
Posted on22 Apr 2016
Comments0
Glenmark Pharmaceuticals has received three observations from the US health regulator for its Pithampur, Indore (India) plant. The Pithampur plant was inspected... Read More
Hummingbird Bioscience and Sanofi’s collaboration for novel cancer therapeutics
Hummingbird Bioscience, an innovative biotechnology company focused on the discovery and early development of antibody therapeutics, announced a collaboration with Sanofi, a... Read More
Swedish firm Recipharm buys Kemwell businesses for Rs 1360 cr
Recipharm AB, a Swedish company, active as a pharmaceutical contract development and manufacturing organisation (CDMO), has agreed to acquire Kemwell’s pharmaceutical contract... Read More
Martindale Pharma signs distribution deal with Saudi Arabia’s Faisal Musaed El Seif Saudi Pharmaceutical
Martindale Pharma, a pharmaceutical company based in the U.K., recently signed a distribution agreement with Faisal Musaed El Seif Saudi Pharmaceutical Co. to... Read More
Boehringer Ingelheim got approval of a supplemental New Drug Application (sNDA) for Gilotrif (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease
Posted on19 Apr 2016
Tagsafatinib, Gilotrif, head to head trial, LUX-Lung 8 trial, sNDA, supplemental New Drug Application
Comments0
Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif (afatinib)... Read More
Promethera Biosciences acquired the key assets of Cytonet GmbH & Co KG
Promethera Biosciences SA, a Belgian biotechnology company developing stem cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired... Read More
Acerus entered into a license and supply agreement with Medinova AG in Canada
Acerus Pharmaceuticals Corporation, a Canadian pharmaceutical company, announced that it has entered into a license and supply agreement with Medinova AG, a... Read More